U.S. Market for Psoriasis Therapeutics to Surpass $9 Billion by 2016

New York, October 20, 2006 — The U.S. incidence of psoriasis and psoriatic arthritis is expected to surge from 7.8 million in 2006 to 8.5 million by 2016. In response, big pharma may be rethinking its strategies as the latest market research shows the potential for the psoriasis therapeutics market to grow from its current $6.5 billion to more than $9 billion by 2016.

According to a new study released today from Kalorama Information, Psoriasis and Psoriatic Arthritis: A Strategic Analysis of the Market in the United States, psoriasis may be moving from a “second string” opportunity to a “first draft” prospect in terms of product development priorities. With the market for current therapeutics highly fragmented—and likely to remain so—newer, more focused therapeutics should have a competitive advantage. Advances in immunology and inflammation research, for example, are fueling new approaches to treatment while stimulating interest in the field.

While considering the overall market value, which includes oft-used OTC and alternative treatments, the research finds that the greatest growth potential is in the Serviceable Available Market (SAM). Defined as those patients whose psoriasis or psoriatic arthritis is treatable only by ethical pharmaceuticals and professional services, this market sector has the potential to jump from $4.7 billion in 2006 to $6.7 billion in 2016, based on the prospect of newly developed therapeutics.

“The current therapeutics market is extremely vulnerable, and advanced psoriasis therapeutics should easily replace many of the existing products used to treat moderate to severe cases,” notes Kenneth G. Krul, Ph.D., the report’s author. “However, while the potential is ripe, in this era of cost-containment and managed care, the market value may be limited somewhat by existing standards.”

Psoriasis and Psoriatic Arthritis provides an extensive discussion on the pathology of the disease and focuses on applications of current and advanced therapeutics. It also provides current and projected cost per patient forecasts; in-depth profiles of major therapeutics competitors; a complete look at current therapies; and trending with strategic implications. It can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1189533.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240.747.3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.